{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dose+Finding+Study&page=19", "query": { "condition": "Dose Finding Study", "page": 19 }, "page_size": 10 }, "pagination": { "page": 19, "page_size": 10, "total_count": 868, "total_pages": 87, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dose+Finding+Study&page=20&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dose+Finding+Study&page=18&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T15:24:56.506Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00006890", "title": "Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "prednisone", "type": "DRUG" }, { "name": "thalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NCIC Clinical Trials Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "16 Years to 120 Years" }, "enrollment_count": 67, "start_date": "2000-07-12", "completion_date": "2008-12-15", "has_results": false, "last_update_posted_date": "2020-04-02", "last_synced_at": "2026-10-23T15:24:56.506Z", "location_count": 1, "location_summary": "Duluth, Minnesota", "locations": [ { "city": "Duluth", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006890" }, { "nct_id": "NCT02932280", "title": "Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "Central Nervous System Tumor", "Lymphoma", "Leukemia" ], "interventions": [ { "name": "Neratinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "3 Years to 21 Years" }, "enrollment_count": 14, "start_date": "2016-10", "completion_date": "2026-10", "has_results": false, "last_update_posted_date": "2025-12-05", "last_synced_at": "2026-10-23T15:24:56.506Z", "location_count": 8, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Palo Alto, California + 5 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Palo Alto", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02932280" }, { "nct_id": "NCT01648322", "title": "Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Neutropenia" ], "interventions": [ { "name": "F-627", "type": "DRUG" }, { "name": "Neulasta® (pegfilgrastim)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EVIVE Biotechnology", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "74 Years", "sex": "FEMALE", "summary": "18 Years to 74 Years · Female only" }, "enrollment_count": 232, "start_date": "2012-06", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2018-10-03", "last_synced_at": "2026-10-23T15:24:56.506Z", "location_count": 1, "location_summary": "Anderson, Indiana", "locations": [ { "city": "Anderson", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01648322" }, { "nct_id": "NCT01962103", "title": "Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neuroblastoma", "Rhabdomyosarcoma", "Ewing's Sarcoma", "Ewing's Tumor", "Sarcoma, Ewing's", "Sarcomas, Epitheliod", "Sarcoma, Soft Tissue", "Sarcoma, Spindle Cell", "Melanoma", "Malignant Melanoma", "Clinical Oncology", "Oncology, Medical", "Pediatrics, Osteosarcoma", "Osteogenic Sarcoma", "Osteosarcoma Tumor", "Sarcoma, Osteogenic", "Tumors", "Cancer", "Neoplasia", "Neoplasm", "Histiocytoma", "Fibrosarcoma", "Dermatofibrosarcoma" ], "interventions": [ { "name": "nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "24 Years", "sex": "ALL", "summary": "6 Months to 24 Years" }, "enrollment_count": 107, "start_date": "2013-12-04", "completion_date": "2018-11-06", "has_results": true, "last_update_posted_date": "2019-12-27", "last_synced_at": "2026-10-23T15:24:56.506Z", "location_count": 2, "location_summary": "Phoenix, Arizona • New York, New York", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01962103" }, { "nct_id": "NCT00591058", "title": "Safety and Dose-Finding Study of TM-601 in Adults With Recurrent Malignant Glioma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Glioma", "Glioblastoma Multiforme", "GBM", "Astrocytoma", "Oligodendroglioma" ], "interventions": [ { "name": "TM-601", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TransMolecular", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2008-02", "completion_date": "2010-02", "has_results": false, "last_update_posted_date": "2009-07-17", "last_synced_at": "2026-10-23T15:24:56.506Z", "location_count": 7, "location_summary": "Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00591058" }, { "nct_id": "NCT07094204", "title": "A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Non-Small-Cell Lung Cancer", "Pancreatic Ductal Adenocarcinoma", "Colorectal Cancer" ], "interventions": [ { "name": "ASP5834", "type": "DRUG" }, { "name": "panitumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 404, "start_date": "2025-07-25", "completion_date": "2029-04-30", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-23T15:24:56.506Z", "location_count": 11, "location_summary": "Santa Monica, California • Atlanta, Georgia • Jefferson, Louisiana + 8 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Jefferson", "state": "Louisiana" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT07094204" }, { "nct_id": "NCT01550185", "title": "Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Acute Basophilic Leukemia", "Adult Acute Eosinophilic Leukemia", "Adult Acute Megakaryoblastic Leukemia (M7)", "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)", "Adult Acute Monoblastic Leukemia (M5a)", "Adult Acute Monocytic Leukemia (M5b)", "Adult Acute Myeloblastic Leukemia With Maturation (M2)", "Adult Acute Myeloblastic Leukemia Without Maturation (M1)", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Acute Myelomonocytic Leukemia (M4)", "Adult Erythroleukemia (M6a)", "Adult Pure Erythroid Leukemia (M6b)", "Recurrent Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "eltrombopag olamine", "type": "DRUG" }, { "name": "standard follow-up care", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2012-05", "completion_date": "2014-12", "has_results": false, "last_update_posted_date": "2022-07-22", "last_synced_at": "2026-10-23T15:24:56.506Z", "location_count": 2, "location_summary": "Atlanta, Georgia • Buffalo, New York", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01550185" }, { "nct_id": "NCT02500316", "title": "Long Term Follow up Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Growth Hormone Deficiency (GHD)" ], "interventions": [ { "name": "MOD-4023", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OPKO Health, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "11 Years", "sex": "ALL", "summary": "3 Years to 11 Years" }, "enrollment_count": 48, "start_date": "2014-02", "completion_date": "2023-11", "has_results": true, "last_update_posted_date": "2025-04-09", "last_synced_at": "2026-10-23T15:24:56.506Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02500316" }, { "nct_id": "NCT06618287", "title": "A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lung Cancer", "Breast Cancer" ], "interventions": [ { "name": "BMS-986507", "type": "DRUG" }, { "name": "Osimertinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Pumitamig", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 416, "start_date": "2025-02-04", "completion_date": "2031-02-26", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-10-23T15:24:56.506Z", "location_count": 14, "location_summary": "Birmingham, Alabama • Miami, Florida • Iowa City, Iowa + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Miami", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT06618287" }, { "nct_id": "NCT07161414", "title": "A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "IV Rilvegostomig", "type": "DRUG" }, { "name": "Recombinant Human Hyaluronidase (rHu)", "type": "DRUG" }, { "name": "SC Rilvegostomig", "type": "DRUG" }, { "name": "SC rilvegostomig + rHu", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2025-11-25", "completion_date": "2029-07-24", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-23T15:24:56.506Z", "location_count": 3, "location_summary": "Huntersville, North Carolina • San Antonio, Texas • Fairfax, Virginia", "locations": [ { "city": "Huntersville", "state": "North Carolina" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07161414" } ] }